Don N. Harris

Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist.

Martin L. Ogletree, Don N. Harris, R Greenberg et al. · Journal of Pharmacology and Experimental Therapeutics · 1985 · 333 citations

Effects of Therapeutic Agents on Cyclic AMP Metabolism In Vitro

Ira Weinryb, Mark Chasin, Charles A. Free et al. · Journal of Pharmaceutical Sciences · 1972 · 96 citations

Biochemistry, Medicine, Physiology +8

EFFECTS OF CHRONIC TREATMENT WITH CAPTOPRIL(SQ 14,225), AN ORALLY ACTIVE INHIBITOR OFANGIOTENSIN I-CONVERTING ENZYME, INSPONTANEOUSLY HYPERTENSIVE RATS

Michael J. Antonaccio, Bernard Rubin, Zola P. Horovitz et al. · The Japanese Journal of Pharmacology · 1979 · 94 citations · Full text

Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets.

Anders Hedberg, S. E. HALL, Martin L. Ogletree et al. · Journal of Pharmacology and Experimental Therapeutics · 1988 · 90 citations · Full text

1-ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)—a potent new inhibitor of cyclic 3′,5′-nucleotide phosphodiesterases

Mark Chasin, Don N. Harris, Marie B. Phillips et al. · Biochemical Pharmacology · 1972 · 83 citations

Molecular Pharmacology, Medicinal Chemistry, Cyclic 3′,5′-Nucleotide Phosphodiesterases +10